VivoSim Labs, Inc. (VIVS)

Akoya Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-2.49	-14.67	-17.26	-11.45	-16.83
Depreciation & Amortization	0.27	0.28	0.29	0.14	0.04
Loss (Gain) From Sale of Assets	-10	-	0.01	-	0.02
Loss (Gain) From Sale of Investments	-0.04	-0.15	-0.13	-	-
Stock-Based Compensation	0.53	1.51	2.38	2.26	5.56
Other Operating Activities	1.23	0.41	-	-	-
Change in Accounts Receivable	0	0.12	-0.15	-	0.11
Change in Inventory	-0.5	-0.3	-	-	-
Change in Accounts Payable	1.02	0.3	-0.15	0.13	-0.44
Change in Other Net Operating Assets	0.52	-2.14	2.61	0.46	-1.79
Operating Cash Flow	-9.46	-14.65	-12.41	-8.45	-13.32
Capital Expenditures	-0.01	-0.04	-0.4	-0.41	-0.41
Sale of Property, Plant & Equipment	9	-	-	-	0.01
Investment in Securities	0.04	0.86	-0.57	-	-
Investing Cash Flow	9.03	0.82	-0.97	-0.41	-0.39
Issuance of Common Stock	8.85	1.44	-	0.25	23.84
Repurchase of Common Stock	-	-	-	-0.05	-0.01
Financing Cash Flow	8.85	1.44	-	0.21	23.84
Net Cash Flow	8.41	-12.4	-13.37	-8.66	10.12
Free Cash Flow	-9.47	-14.7	-12.8	-8.86	-13.73
Free Cash Flow Margin	-6579.17%	-13481.65%	-3460.54%	-590.80%	-
Free Cash Flow Per Share	-6.47	-19.28	-17.63	-12.22	-23.87
Cash Interest Paid	0.01	-	-	-	-
Cash Income Tax Paid	0	0	0	0	0
Levered Free Cash Flow	-5.03	-9.5	-6.72	-4.83	-4.73
Unlevered Free Cash Flow	-5.02	-9.5	-6.72	-4.83	-4.73
Change in Net Working Capital	-2.08	1.82	-2.09	-0.36	1.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.